TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions andAssumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1 Prevalence of BreastCancer Therapeutics by Key Countries 4.2 Regulatory Scenario byKey Regions 4.3 Key IndustryDevelopments 4.4 Overview of CurrentAdvances in R&D for Breast Cancer Therapeutics 5. Global Breast Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis,Insights and Forecast – By Therapy 5.2.1Targeted Therapy 5.2.1.1 Abemaciclib 5.2.1.2 Ado-Trastuzumab Emtansine 5.2.1.3 Everolimus 5.2.1.4 Trastuzumab 5.2.1.5 Ribociclib 5.2.1.6 Palbociclib 5.2.1.7 Pertuzumab 5.2.1.8 Olaparib 5.2.1.9 Others 5.2.2 Hormonal Therapy 5.2.2.1 Selective Estrogen Receptor Modulators (SERMs) 5.2.2.2 Aromatase Inhibitors 5.2.2.3 Estrogen Receptor Downregulators (ERDs) 5.2.3 Chemotherapy 5.3. Market Analysis,Insights and Forecast – By Distribution Channel 5.3.1 Hospital Pharmacies 5.3.2 Retail Pharmacies 5.3.3 Online Pharmacies 5.3.4 Others 5.4 Market Analysis,Insights and Forecast – By Cancer Type 5.4.1 Hormone Receptor 5.4.2 HER2+ 5.5. Market Analysis,Insights and Forecast – By Region 5.5.1 North America 5.5.2 Europe 5.5.3 Asia Pacific 5.5.4 Latin America 5.5.5 Middle East & Africa 6. North America Breast Cancer Therapeutics Market Analysis, Insights andForecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – ByTherapy 6.2.1 Targeted Therapy 6.2.1.1 Abemaciclib 6.2.1.2 Ado-Trastuzumab Emtansine 6.2.1.3 Everolimus 6.2.1.4 Trastuzumab 6.2.1.5 Ribociclib 6.2.1.6 Palbociclib 6.2.1.7 Pertuzumab 6.2.1.8 Olaparib 6.2.1.9 Others 6.2.2 Hormonal Therapy 6.2.2.1 Selective Estrogen Receptor Modulators (SERMs) 6.2.2.2 Aromatase Inhibitors 6.2.2.3 Estrogen Receptor Downregulators (ERDs) 6.2.3 Chemotherapy 6.3. Market Analysis – By Distribution Channel 6.3.1 Hospital Pharmacies 6.3.2 Retail Pharmacies 6.3.3 Online Pharmacies 6.3.4 Others 6.4. Market Analysis – By Cancer Type 6.4.1 Hormone Receptor 6.4.2 HER2+ 6.5. Market Analysis – By Country 6.5.1 U.S 6.5.2 Canada 7. Europe Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – ByTherapy 7.2.1 Targeted Therapy 7.2.1.1 Abemaciclib 7.2.1.2 Ado-Trastuzumab Emtansine 7.2.1.3 Everolimus 7.2.1.4 Trastuzumab 7.2.1.5 Ribociclib 7.2.1.6 Palbociclib 7.2.1.7 Pertuzumab 7.2.1.8 Olaparib 7.2.1.9 Others 7.2.2 Hormonal Therapy 7.2.2.1Selective Estrogen Receptor Modulators (SERMs) 7.2.2.2Aromatase Inhibitors 7.2.2.3Estrogen Receptor Downregulators (ERDs) 7.2.3 Chemotherapy 7.3. Market Analysis – ByDistribution Channel 7.3.1 Hospital Pharmacies 7.3.2 Retail Pharmacies 7.3.3 Online Pharmacies 7.3.4 Others 7.4. Market Analysis – ByCancer Type 7.4.1 Hormone Receptor 7.4.2 HER2+ 7.5. Market Analysis – ByCountry/Sub-region 7.5.1Germany 7.5.2 U.K. 7.5.3 France 7.5.4 Italy 7.5.5 Spain 7.5.6 Scandinavia 7.5.7 Rest of Europe 8. Asia Pacific Breast Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – ByTherapy 8.2.1 Targeted Therapy 8.2.1.1 Abemaciclib 8.2.1.2 Ado-Trastuzumab Emtansine 8.2.1.3 Everolimus 8.2.1.4 Trastuzumab 8.2.1.5 Ribociclib 8.2.1.6 Palbociclib 8.2.1.7 Pertuzumab 8.2.1.8 Olaparib 8.2.1.9 Others 8.2.2 Hormonal Therapy 8.2.2.1 Selective Estrogen Receptor Modulators (SERMs) 8.2.2.2 Aromatase Inhibitors 8.2.2.3 Estrogen Receptor Downregulators (ERDs) 8.2.3 Chemotherapy 8.3. Market Analysis – By Distribution Channel 8.3.1 Hospital Pharmacies 8.3.2 Retail Pharmacies 8.3.3 Online Pharmacies 8.3.4 Others 8.4. Market Analysis – By Cancer Type 8.4.1 Hormone Receptor 8.4.2 HER2+ 8.5. Market Analysis – ByCountry/Sub-region 8.5.1China 8.5.2 India 8.5.3 Japan 8.5.4 Australia 8.5.5 Southeast Asia 8.5.6 Rest of Asia Pacific 9. Latin America Breast Cancer Therapeutics Market Analysis, Insights andForecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – ByTherapy 9.2.1 Targeted Therapy 9.2.1.1 Abemaciclib 9.2.1.2 Ado-Trastuzumab Emtansine 9.2.1.3 Everolimus 9.2.1.4 Trastuzumab 9.2.1.5 Ribociclib 9.2.1.6 Palbociclib 9.2.1.7 Pertuzumab 9.2.1.8 Olaparib 9.2.1.9 Others 9.2.2 Hormonal Therapy 9.2.2.1 Selective Estrogen Receptor Modulators (SERMs) 9.2.2.2 Aromatase Inhibitors 9.2.2.3 Estrogen Receptor Downregulators (ERDs) 9.2.3 Chemotherapy 9.3. Market Analysis – By Distribution Channel 9.3.1 Hospital Pharmacies 9.3.2 Retail Pharmacies 9.3.3 Online Pharmacies 9.3.4 Others 9.4. Market Analysis – By Cancer Type 9.4.1 Hormone Receptor 9.4.2 HER2+ 9.5. Market Analysis – By Country/ Sub-Region 9.5.1 Brazil 9.5.2 Mexico 9.5.3 Rest of Latin America 10. MiddleEast & Africa Breast Cancer Therapeutics Market Analysis, Insights andForecast, 2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – ByTherapy 10.2.1Targeted Therapy 10.2.1.1 Abemaciclib 10.2.1.2 Ado-Trastuzumab Emtansine 10.2.1.3 Everolimus 10.2.1.4 Trastuzumab 10.2.1.5 Ribociclib 10.2.1.6 Palbociclib 10.2.1.7 Pertuzumab 10.2.1.8 Olaparib 10.2.1.9 Others 10.2.2 Hormonal Therapy 10.2.2.1 Selective EstrogenReceptor Modulators (SERMs) 10.2.2.2 Aromatase Inhibitors 10.2.2.3 Estrogen Receptor Downregulators (ERDs) 10.2.3 Chemotherapy 10.3. Market Analysis – By Distribution Channel 10.3.1 Hospital Pharmacies 10.3.2 Retail Pharmacies 10.3.3 Online Pharmacies 10.3.4 Others 10.4. Market Analysis – By Cancer Type 10.4.1 Hormone Receptor 10.4.2 HER2+ 10.5. Market Analysis – By Country/ Sub-region 10.5.1 South Africa 10.5.2 GCC Countries 10.5.3 Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments,strategies, financials (based on availability)) 11.5.1 Genentech, Inc. (F. Hoffmann-La Roche Ltd) 11.5.2 Eli Lilly and Company 11.5.3 Celgene Corporation 11.5.4 AstraZeneca 11.5.5 Pfizer Inc. 11.5.6 Sanofi 11.5.7 Eisai Co. Ltd. 11.5.8 Kyowa Kirin 11.5.9 Bristol Myers Squibb 11.5.10 Mayne Pharma Group Limited 11.5.11 Valeant Pharmaceuticals 11.5.12 Other Prominent Players 12. Strategic Recommendations

Genentech (F. Hoffmann-La Roche Ltd) Eli Lilly and Company Celgene Corporation AstraZeneca Pfizer Inc. Sanofi Eisai Co. Ltd. Kyowa Kirin Bristol Myers Squibb Mayne Pharma Group Limited Novartis AG Valeant Pharmaceuticals